Toth L, Mokanszki A, Mehes G
Pathol Oncol Res. 2024; 30:1611733.
PMID: 38953007
PMC: 11215025.
DOI: 10.3389/pore.2024.1611733.
Parvaresh H, Roozitalab G, Golandam F, Behzadi P, Jabbarzadeh Kaboli P
Biomedicines. 2024; 12(2).
PMID: 38397899
PMC: 10887432.
DOI: 10.3390/biomedicines12020297.
Zabeirou A, Efared B, Souiki T, James Didier L, Majdoub K, Toughrai I
Ann Med Surg (Lond). 2023; 85(12):6237-6242.
PMID: 38098604
PMC: 10718341.
DOI: 10.1097/MS9.0000000000001416.
Piccaluga P, Cascianelli C, Inghirami G
Front Oncol. 2023; 13:1099943.
PMID: 36845713
PMC: 9946040.
DOI: 10.3389/fonc.2023.1099943.
Xing P, Zhao Q, Zhang L, Wang H, Huang D, Hu P
BMC Med. 2022; 20(1):453.
PMID: 36424628
PMC: 9694544.
DOI: 10.1186/s12916-022-02646-0.
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.
Papageorgiou S, Pashley S, ORegan L, Khan S, Bayliss R, Fry A
Cancers (Basel). 2022; 14(14).
PMID: 35884511
PMC: 9325236.
DOI: 10.3390/cancers14143452.
Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments.
Latif M, Ashraf Z, Basit S, Ghaffar A, Zafar M, Saeed A
RSC Adv. 2022; 8(30):16470-16493.
PMID: 35540549
PMC: 9080316.
DOI: 10.1039/c8ra01934g.
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors.
Hurtado F, De Braud F, de Castro Carpeno J, De Miguel Luken M, Wang D, Scott J
Cancer Chemother Pharmacol. 2021; 87(4):475-486.
PMID: 33394101
PMC: 7946667.
DOI: 10.1007/s00280-020-04180-3.
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.
Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L
Cancers (Basel). 2019; 11(6).
PMID: 31167506
PMC: 6627883.
DOI: 10.3390/cancers11060775.
Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.
Nikitski A, Rominski S, Wankhede M, Kelly L, Panebianco F, Barila G
Am J Pathol. 2018; 188(11):2653-2661.
PMID: 30125543
PMC: 6222272.
DOI: 10.1016/j.ajpath.2018.07.012.
ALK-rearrangement in non-small-cell lung cancer (NSCLC).
Du X, Shao Y, Qin H, Tai Y, Gao H
Thorac Cancer. 2018; 9(4):423-430.
PMID: 29488330
PMC: 5879058.
DOI: 10.1111/1759-7714.12613.
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L, Fenner S, Ratcliffe S, Isidro-Llobet A, Hann M, Bax B
Nucleic Acids Res. 2018; 46(5):2218-2233.
PMID: 29447373
PMC: 5861436.
DOI: 10.1093/nar/gky072.
Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.
Ross J, Ali S, Fasan O, Block J, Pal S, Elvin J
Oncologist. 2017; 22(12):1444-1450.
PMID: 29079636
PMC: 5728036.
DOI: 10.1634/theoncologist.2016-0488.
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.
Hsu J, Hung M
Cancer Metastasis Rev. 2016; 35(4):575-588.
PMID: 27913999
PMC: 5215954.
DOI: 10.1007/s10555-016-9649-6.
Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth.
Hayashi Y, Kawakubo-Yasukochi T, Mizokami A, Takeuchi H, Nakamura S, Hirata M
J Cancer. 2016; 7(12):1605-1609.
PMID: 27698897
PMC: 5039381.
DOI: 10.7150/jca.15523.
Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.
Buetti-Dinh A, OHare T, Friedman R
PLoS One. 2016; 11(9):e0163011.
PMID: 27669408
PMC: 5036789.
DOI: 10.1371/journal.pone.0163011.
The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers.
Alshareef A, Zhang H, Huang Y, Wu C, Zhang J, Wang P
Sci Rep. 2016; 6:33710.
PMID: 27641368
PMC: 5027386.
DOI: 10.1038/srep33710.
Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.
Singh V, Werner S, Hackstein H, Lennerz V, Reiter A, Wolfel T
Clin Exp Immunol. 2016; 186(1):96-105.
PMID: 27414060
PMC: 5011366.
DOI: 10.1111/cei.12842.
Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.
Schaefer E, Baik C
Cancer Manag Res. 2016; 8:33-8.
PMID: 27069372
PMC: 4818057.
DOI: 10.2147/CMAR.S96471.
Analysis of clinicopathological features of the echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase fusion gene in Chinese patients with advanced non-small-cell lung cancer.
Liu Y, Shi Y, Hao X, Wang L, Li J, Han X
Thorac Cancer. 2016; 5(3):255-60.
PMID: 26767009
PMC: 4704311.
DOI: 10.1111/1759-7714.12101.
